- Oxford Immunotec (NASDAQ:OXFD) and Qiagen (QGEN) have settled their lawsuit over patent infringement in the case of Qiagen's QuantiFERON-TB Gold and Gold Plus products.
- As part of the deal, which settles all pending claims, Oxford grants Qiagen a royalty-free nonexclusive license for a one-time payment of $27.5M.
- The license covers all current and future customers of QuantiFERON-TB Gold and Gold Plus.
- Previously: Oxford loses bid to prevent Qiagen from selling QFT-Plus TB test before patent infringement trial, but likely to prevail in the case (Sep. 27 2017)